About US
Contact us
-
News of Note—UCB's $300M plant; AbbVie's latest Rinvoq nod; Biogen's $5B buyback>UCBis investing more than €300 million ($333 million) to build a new biologics manufacturing facility at its site in Braine l’Alleud, Belgium. Expected to start operating in 2024, the plant will2019/12/25
-
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdlesIn January 2019, then-FDA commissioner Scott Gottlieb ushered in the new year with a bold prediction: The agency, he said, would be approving between 10 and 20 gene and cell therapies per year by 2022019/12/24
-
ArQule wanted a partner. Merck wanted control. Solution? A buyout dealIt’s not uncommon for partnership talks focused on one drug to escalate into a full-on buyout. And that's just what happened with Merck & Co.’s $2.7 billion deal for ArQule. ArQule started lookin2019/12/24
-
Lilly launches real-world study to benchmark Emgality against migraine rivalsEli Lilly’s CGRP migraine prevention medEmgalitytrailed its rivals onto the market, but it’s been a force in the dogfight for market share. Now,in an effort tolearn more about how physicians choose b2019/12/23
-
Zolgensma for free? Yes, but advocates worry about Novartis' lottery-style giveawayLong before Novartiswon its first approval for gene therapyZolgensma, thedrugmakerfaced questions about how it would price a one-time cure for spinal muscular atrophy, adevastating rare disease. Then2019/12/23
-
Sense or 'nonsense'? Senators blast Lilly's generic insulin, but CEO Ricks strikes backInsulin producers have faced years of negative headlines as prices and rebates rose in lockstep.So Eli Lilly tried to thwart the rebate effect with ahalf-priced version of its top insulin Humalog—and2019/12/20
-
GlaxoSmithKline's Benlysta eyes lupus sales boost after kidney trial winGlaxoSmithKline's Benlysta has long enjoyed its place as the sole biologic approved to treat lupus, despite other drugmakers' forays into the field. But with competitors sniffing around, GSK is looki2019/12/20
-
ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysisGENEVA—Since unveiling its Tecentriqmonotherapy win in previously untreated non-small lung cancer, Roche has faced criticism that the diagnostic test it used to identify trial patients might have inf2019/12/19
-
AZ, Merck's Lynparza narrowly snags FDA panel backing in pancreatic cancerAstraZeneca and Merck’s Lynparza is looking to become thefirstin its class of PARP inhibitors to break into the pancreatic cancer market. And a majority of FDA advisers thinks it should be—if only a2019/12/19
-
Roche's $4.3B Spark deal wins U.K. antitrust clearance, foreshadowing a similar FTC moveAfter months of delays, Roche has won the first major antitrust clearance for its proposed $4.3 billion buyout of Spark Therapeutics. Monday, the U.K.’s Competition and Markets Authority (CMA) said i2019/12/18